Show simple item record

Why methylene blue should be blacklisted in neonatology

dc.contributor.authorSilecchia, Valeria
dc.contributor.authorValerio, Enrico
dc.contributor.authorMerazzi, Daniele
dc.contributor.authorIantorno, Lorenzo
dc.contributor.authorLaguardia, Maria Chiara
dc.contributor.authorCutrone, Mario
dc.contributor.authorGrimalt Santacana, Ramon
dc.date.accessioned2020-06-23T10:14:43Z
dc.date.available2020-06-23T10:14:43Z
dc.date.issued2019
dc.identifier.citationSilecchia, Valeria; Valerio, Enrico; Merazzi, Daniele [et al.]. Why methylene blue should be blacklisted in neonatology. Journal of Respiratory Research, 2019. 5(1), p. 1-2. Disponible en: <http://www.ghrnet.org/index.php/jdr/article/view/2731/3037>. Fecha de acceso: 23 jun. 2020. DOI:10.17554/j.issn.2412-2424.2019.05.46-5ca
dc.identifier.issn2412-2424ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/1601
dc.description.abstractWe here present a case of neonatal skin damage due to application of methylene blue (MB) on a newborn's skin. MB use should be completely eliminated in neonatal intensive care units and nurseries, because of three potentially dangerous adverse effects of this compound: (1) It may act as an irritant when applied topically on intact skin, leading to skin reddening up to deep full-thickness eschars; (2) Is possesses photosensitizing properties, and may produce skin reddening followed by blisters and peeling after UV phototherapy; (3) It is a proscribed substance in patients affected by glucose-6-phosphate dehydrogenase deficiency, a condition not easily detected in the very first days of life.ca
dc.format.extent2ca
dc.language.isoengca
dc.publisherACT Publishing Group Limitedca
dc.relation.ispartofJournal of Respiratory Researchca
dc.relation.ispartofseries5;1
dc.rights© 2018 The Author(s). Published by ACT Publishing Group Ltd. All rights reserved. This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: http://creativecommons.org/licenses/by-nc/4.0/ca
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.otherNeonatologiaca
dc.subject.otherDermatologiaca
dc.subject.otherPediatria intensivaca
dc.subject.otherNeonatología
dc.subject.otherDermatología
dc.subject.otherCuidados intensivos neonatales
dc.subject.otherNeonatology
dc.subject.otherDermatology
dc.subject.otherIntensive care, neonatal
dc.titleWhy methylene blue should be blacklisted in neonatologyca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/acceptedVersionca
dc.embargo.termscapca
dc.subject.udc61ca
dc.identifier.doihttp://dx.doi.org/10.17554/j.issn.2412-2424.2019.05.46-5ca


Files in this item

 
Name:
Grimalt Santacana, Ramon [et ...
Size:
722.6Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record

© 2018 The Author(s). Published by ACT Publishing Group Ltd. All rights reserved. This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint